Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: Improvement in the sensitivity or specificity?

Wu, Gang; Wang, Jie; Zhou, Zhongwen; Li, Tianyi; Tang, Feng

doi:10.1177/0300060513490617

Cited by 23 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some ancillary approaches (such as immunohistochemistry and molecular techniques) have been explored. [9] In our study, the highest frequency of cases (49.9%) was seen in 31-40 years of age group. These findings are in concordance with the studies done by Ramesh et al, [10] Wani et al [11] and Kolur et al [12] Wani et al and Ramesh et al analyzed that the relative peak incidence was seen in 30-39 years age group.…”

Section: Discussionsupporting

confidence: 47%

Application of CK 19 and CD 56 Immunohistochemical Markers in the Diagnosis of Thyroid Tumors

Dalal¹

2018

jmscr

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 47%

Application of CK 19 and CD 56 Immunohistochemical Markers in the Diagnosis of Thyroid Tumors

Dalal¹

2018

jmscr

View full text Add to dashboard Cite

“…The reasons for the discrepancies in CK19 expression and postsurgical course of PTC are not epitope-1, have some significance in differentiating thyroid carcinomas and have been widely described [20,35,36]. However, their value as prognostic factors of the aggressive course of PTC has not been clearly established [2,20,[34][35][36].…”

Section: Discussionmentioning

confidence: 99%

“…However, their value as prognostic factors of the aggressive course of PTC has not been clearly established [2,20,[34][35][36]. Knowledge of high aggressiveness in PTC and the high probability of its early recurrence -even after early primary surgical treatment -may improve the effectiveness of further treatment.…”

Section: Discussionmentioning

confidence: 99%

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region

Kaliszewski

Diakowska

Strutyńska−Karpińska

et al. 2017

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Introduction. Cytokeratin-19 (CK19) is recognized as a reliable tumor marker of papillary thyroid carcinoma (PTC). The general prognosis in the classical subtype of PTC (CSTPTC) remains favorable, but some cases can be very aggressive. The aim of this study was to evaluate the localization and intensity of immunohistochemical CK19 expression in CSTPTC and its associations with the clinical and pathological characteristics of patients with CSTPTC in the Silesian region. Material and methods. All the available clinical and histopathological data for 149 patients with CSTPTC from the Silesian region were retrospectively analyzed. The group consisted of 135 (90.6%) women and 14 (9.4%) men (mean age and SD: 52.3 ± 15.0). All these patients with CSTPTC underwent surgery at the same center between 2008 and 2013; the follow-up period was 24 to 90 months (mean and SD: 47 ± 20). Results. In 142 (95.3%) of the patients with CSTPTC, positive cytoplasmic staining of CK19 was found. A higher expression of CK19 was observed in the group of patients without the recurrence of the disease (p = 0.015). CK19 expression was not associated with age, gender, tumor focality, disease stage, tumor size (pT), lymph node involvement (pN), or distant metastases (pM). Conclusions. Decreased CK19 expression in CSTPTC cases with relapse suggests that it plays a role in the carcinoma progression of CSTPTC. The association between lower CK19 expression and patients' unfavorable postoperative course could suggest its possible role as a marker of CSTPTC poor prognosis.

show abstract

“…To date, many studies have evaluated HER2 expression in thyroid cancer with controversial results, largely due to inter-study differences in the size and setting of the examined series and, most of all, to the subjective assessment and lack of uniform methodology [14,15,16,17,18,19,20,21,22,23,24,25,26]. Indeed, studies reported in the literature in the past several decades markedly differ by the methodological approach used to assess HER2 status [14,15,16,17,18,19,20,21,22,23,24,25,26].…”

Section: Discussionmentioning

confidence: 99%

“…Studies on HER2 have also been performed in thyroid cancer cells and tissues [14,15,16,17,18,19,20,21,22,23,24,25,26]. Interestingly, a wide variation in HER2 overexpression was reported in such studies, with positivity rates varying from 0% up to 70%, which may largely be attributed to inter-study technical and interpretive variations.…”

Section: Introductionmentioning

confidence: 99%

HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin

Ruggeri

Campennì

Giuffrè

et al. 2016

IJMS

View full text Add to dashboard Cite

The Epidermal Growth Factor Receoptor (EGFR) family member human epidermal growth factor receptor 2 (HER2) is overexpressed in many human epithelial malignancies, representing a molecular target for specific anti-neoplastic drugs. Few data are available on HER2 status in differentiated thyroid cancer (DTC). The present study was aimed to investigate HER2 status in sporadic cancers of follicular cell origin to better clarify the role of this receptor in the stratification of thyroid cancer. By immunohistochemistry and fluorescence in-situ hybridization, HER2 expression was investigated in formalin-fixed paraffin-embedded surgical specimens from 90 DTC patients, 45 follicular (FTC) and 45 papillary (PTC) histotypes. No HER2 immunostaining was recorded in background thyroid tissue. By contrast, overall HER2 overexpression was found in 20/45 (44%) FTC and 8/45 (18%) PTC, with a significant difference between the two histotypes (p = 0.046). Five of the six patients who developed metastatic disease during a median nine-year follow-up had a HER2-positive tumor. Therefore, we suggest that HER2 expression may represent an additional aid to identify a subset of patients who are characterized by a worse prognosis and are potentially eligible for targeted therapy.

show abstract

Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: Improvement in the sensitivity or specificity?

Abstract: The combination of HBME-1 and either CK19 or galectin-3 or HER-2/neu can improve the specificity of the diagnosis of PTC.

Cited by 23 publications

References 39 publications

Application of CK 19 and CD 56 Immunohistochemical Markers in the Diagnosis of Thyroid Tumors

Application of CK 19 and CD 56 Immunohistochemical Markers in the Diagnosis of Thyroid Tumors

Expression of cytokeratin-19 (CK19) in the classical subtype of papillary thyroid carcinoma: the experience of one center in the Silesian region

HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin

Contact Info

Product

Resources

About